(NASDAQ: NEO) Neogenomics's forecast annual revenue growth rate of 10.28% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 5.28%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.45%.
Neogenomics's revenue in 2024 is $591,643,000.On average, 6 Wall Street analysts forecast NEO's revenue for 2024 to be $83,569,900,391, with the lowest NEO revenue forecast at $83,074,135,389, and the highest NEO revenue forecast at $83,980,166,666. On average, 6 Wall Street analysts forecast NEO's revenue for 2025 to be $91,973,659,509, with the lowest NEO revenue forecast at $91,266,699,893, and the highest NEO revenue forecast at $92,517,278,275.
In 2026, NEO is forecast to generate $99,764,252,390 in revenue, with the lowest revenue forecast at $99,472,025,401 and the highest revenue forecast at $100,056,479,379.